Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer

Chimeric antigen receptors (CARs) that retarget T cells against CD19 show clinical efficacy against B cell malignancies. Here, we describe the development of a CAR against the six-transmembrane epithelial antigen of prostate-1 (STEAP1), which is expressed in ∼90% of prostate cancers, and subgroups o...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yixin, Lorvik, Kristina Berg, Jin, Yang, Beck, Carole, Sike, Adam, Persiconi, Irene, Kvaløy, Emilie, Saatcioglu, Fahri, Dunn, Claire, Kyte, Jon Amund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278049/
https://www.ncbi.nlm.nih.gov/pubmed/35860008
http://dx.doi.org/10.1016/j.omto.2022.06.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278049/
https://www.ncbi.nlm.nih.gov/pubmed/35860008
http://dx.doi.org/10.1016/j.omto.2022.06.007

Ejemplares similares